{"DataElement":{"publicId":"2006142","version":"2","preferredName":"Anticonvulsant Medication Received Ind-2","preferredDefinition":"the yes/no indicator that asks whether the patient is receiving enzyme-inducing anticonvulsant medication.","longName":"ACON_MEDS_RECD_IND-2","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2014035","version":"1","preferredName":"Medication Received","preferredDefinition":"the medication received by the patient.","longName":"MEDS_RECD","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2177035","version":"1","preferredName":"Medication","preferredDefinition":"A drug or substance that treats or prevents or alleviates the symptoms of disease.","longName":"Medication","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Medication","conceptCode":"C459","definition":"A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7A94-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2184327","version":"1","preferredName":"Received","preferredDefinition":"Received; taken, gotten, or acquired.","longName":"Received","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-1F66-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B309B731-D973-0FEF-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4104894","version":"1","longName":"GOG-0231D","context":"NRG"}]},{"publicId":"4254096","version":"1","longName":"Protocol Phase","context":"PBTC","ClassificationSchemeItems":[{"publicId":"10000103","version":"1","longName":"Phase I","context":"PBTC"},{"publicId":"4254119","version":"1","longName":"PBTC-042","context":"PBTC"}]}],"AlternateNames":[{"name":"caBIG","type":"USED_BY","context":"NCIP"},{"name":"ACON_MEDS_RECD_IND-2","type":"C3D Name","context":"NCIP"},{"name":"ACON_MEDS_RECD_IND-2","type":"USED_BY","context":"CTEP"},{"name":"PBTC","type":"USED_BY","context":"PBTC"},{"name":"ACON_MEDS_RECD_IND-2","type":"USED_BY","context":"COG"},{"name":"ACON_MEDS_RECD_IND-2","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"Is patient receiving enzyme-i","type":"Preferred Question Text","description":"Is patient receiving enzyme-inducing anticonvulsant drugs?","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Currently on enzyme inducing anti-convulsants or other strong inducers (efavirenz, nevirapine, barbiturates, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, pioglitazone) or strong inhibitors of CYP3A4 (indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, saquinavir, telithromycin).  (See http://medicine.iupui.edu/clinpharm/ddis/table.asp for an up-to-date list of strong inducers and inhibitors of CYP3A4.)","url":null,"context":"CTEP"},{"name":"CRF Text3","type":"Alternate Question Text","description":"Will the patient receive treatment with clinically significant enzyme inducers, such as the enzyme-inducing antiepileptic drugs phenytoin, carbamazepine, oxcarbazepine, primidone or phenobarbital, or rifampin, rifabutin, rifapentine, or St. John's wort within 14 days prior to the first dose of MLN8237 or during the study?","url":null,"context":"CTEP"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Has the patient received treatment with clinically significant enzyme inducers, such as the enzyme-inducing antiepileptic drugs phenytoin, carbamazepine, oxcarbazepine, primidone or phenobarbital, or rifampin, rifabutin, rifapentine, or St. John's wort within 14 days prior to the first dose of MLN8237 or during the study?","url":null,"context":"CTEP"},{"name":"COG_CRF_TEXT_1","type":"Alternate Question Text","description":"Is patient receiving non-enzyme inducing anticonvulsant drugs","url":null,"context":"CTEP"},{"name":"COG CRF Text_1","type":"Alternate Question Text","description":"Is patient receiving anticonvulsant drugs","url":null,"context":"CTEP"},{"name":"PBTC_Text1","type":"Alternate Question Text","description":"Does patient require enzyme inducing anti-convulsants to control seizures?","url":null,"context":"PBTC"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Is patient receiving anticonvulsant drugs?","url":null,"context":"COG"},{"name":"COG CRF Text 4","type":"Alternate Question Text","description":"Is patient receiving non-enzyme inducing anticonvulsant drugs?","url":null,"context":"COG"},{"name":"COG CRF Text 5","type":"Alternate Question Text","description":"Does the patient require anti-convulsants to control seizures?","url":null,"context":"COG"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"Has the patient received enzyme-inducing anticonvulsants within 14 days prior to enrollment?","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"BEE4C2EB-EB8F-117D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-05-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-05-30","modifiedBy":"KUMMEROA","dateModified":"2022-08-31","changeDescription":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":"2022.8.31 AQT added per ticket request CADSR-TASK0001488. ak","unresolvedIssues":null,"deletedIndicator":"No"}}